头颈癌T细胞免疫治疗耐药机制
本文综述头颈鳞状细胞癌T细胞免疫治疗的耐药机制。多数患者无法获得持久缓解,免疫编辑可清除敏感克隆而留下耐药克隆,这些克隆可能仍对NK细胞敏感。免疫抑制微环境通过多种机制削弱效应免疫应答,高效免疫治疗可能需要靶向独立免疫激活机制的多模式策略。
要点
- T细胞免疫治疗在多数头颈鳞癌患者中不能获得持久缓解。
- 免疫编辑清除T细胞敏感克隆,留下耐药克隆。
- 耐药克隆可能仍对NK细胞敏感,提示T与NK联合治疗可能获益。
核心结论
- 高效免疫治疗可能需要靶向独立免疫激活机制的多模式策略。
研究设计与样本
- 综述,纳入涵盖肿瘤异质性、免疫编辑、免疫逃逸和局部肿瘤免疫抑制的原创文章。
主要发现
- 在免疫压力下,对T细胞杀伤敏感的亚克隆被清除,留下耐药肿瘤克隆,即免疫编辑。
- 对T细胞杀伤耐药的肿瘤亚克隆可能仍对NK细胞检测和清除敏感。
- 即使免疫治疗最优,免疫抑制性肿瘤微环境仍可通过多种不同机制削弱效应免疫应答。
临床怎么用
- 携带对T细胞杀伤耐药但可能对NK细胞敏感肿瘤的患者,可考虑T细胞与NK细胞免疫治疗联合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most current approved or investigational immunotherapeutic approaches for head and neck squamous cell carcinoma are aimed at activating T cells. The majority of patients receiving such immunotherapy do not demonstrate durable tumor remission. METHODS: Original articles covering tumor heterogeneity, immunoediting, immune escape, and local tumor immunosuppression were reviewed. RESULTS: In the face of immune pressure, subclones susceptible to T cell killing are eliminated, leaving behind resistant tumor clones in a process known as immunoediting. Such subclones of tumor cells that are resistant to T cell killing may remain sensitive to natural killer (NK) cell detection and elimination, suggesting that patients harboring such tumors may benefit from combination of T and NK cell-based immunotherapy. Even in the setting of optimal immunotherapy, the immunosuppressive tumor microenvironment may arrogate effector immune responses through a number of distinct mechanisms. CONCLUSIONS: Highly effective immunotherapy will likely require multimodality approaches targeting independent mechanisms of immune activation.
引用
- Lee MY, Allen CT. Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer. Head Neck. 2020. PMID: 32275098. doi:10.1002/hed.26158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。